Phase 1 study of the anti-vascular endothelial growth factor receptor 3 monoclonal antibody LY3022856/IMC-3C5 in patients with advanced and refractory solid tumors and advanced colorectal cancer
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Phase 1 study of the anti-vascular endothelial growth factor receptor 3 monoclonal antibody LY3022856/IMC-3C5 in patients with advanced and refractory solid tumors and advanced colorectal cancer
Authors
Keywords
Colorectal cancer, Vascular endothelial growth factor (VEGF), Monoclonal antibody, Lymphangiogenesis
Journal
CANCER CHEMOTHERAPY AND PHARMACOLOGY
Volume 78, Issue 4, Pages 815-824
Publisher
Springer Nature
Online
2016-08-26
DOI
10.1007/s00280-016-3134-3
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2015) Jin Li et al. LANCET ONCOLOGY
- Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma
- (2015) Toni K. Choueiri et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer
- (2015) Martin Schlumberger et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety profile of combined therapy inhibiting EFGR and VEGF pathways in patients with advanced non-small-cell lung cancer: A meta-analysis of 15 phase II/III randomized trials
- (2014) Wang Ma et al. INTERNATIONAL JOURNAL OF CANCER
- Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial
- (2014) Martin Reck et al. LANCET ONCOLOGY
- Understanding and managing toxicities of vascular endothelial growth factor (VEGF) inhibitors
- (2013) Manuela Schmidinger EJC SUPPLEMENTS
- Is the sentinel lymph node pathology protocol in breast cancer patients associated with the risk of regional recurrence?
- (2013) M.J. Bolster et al. EJSO
- Tivozanib Versus Sorafenib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma: Results From a Phase III Trial
- (2013) Robert J. Motzer et al. JOURNAL OF CLINICAL ONCOLOGY
- Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial
- (2013) Charles S Fuchs et al. LANCET
- Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial
- (2013) Thomas E Hutson et al. LANCET ONCOLOGY
- Inhibition of angiogenesis by a novel neutralizing antibody targeting human VEGFR-3
- (2013) Hao Chen et al. mAbs
- Lymphangiogenesis and lymphovascular invasion diminishes prognosis in esophageal cancer
- (2013) Sebastian F. Schoppmann et al. SURGERY
- SAR131675, a Potent and Selective VEGFR-3-TK Inhibitor with Antilymphangiogenic, Antitumoral, and Antimetastatic Activities
- (2012) A. Alam et al. MOLECULAR CANCER THERAPEUTICS
- Angiogenesis, lymphangiogenesis, growth pattern, and tumor emboli in inflammatory breast cancer
- (2010) Peter B. Vermeulen et al. CANCER
- Lymphangiogenesis: Molecular Mechanisms and Future Promise
- (2010) Tuomas Tammela et al. CELL
- Vascular Endothelial Growth Factor Receptors VEGFR-2 and VEGFR-3 Are Localized Primarily to the Vasculature in Human Primary Solid Cancers
- (2010) N. R. Smith et al. CLINICAL CANCER RESEARCH
- Phase I Pharmacologic and Biologic Study of Ramucirumab (IMC-1121B), a Fully Human Immunoglobulin G1Monoclonal Antibody Targeting the Vascular Endothelial Growth Factor Receptor-2
- (2010) Jennifer L. Spratlin et al. JOURNAL OF CLINICAL ONCOLOGY
- Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial
- (2010) Cora N. Sternberg et al. JOURNAL OF CLINICAL ONCOLOGY
- Prognostic classifications of lymph node involvement in lung cancer and current International Association for the Study of Lung Cancer descriptive classification in zones
- (2010) Marc Riquet et al. Interactive Cardiovascular and Thoracic Surgery
- VEGF-C and VEGF-D expression is correlated with lymphatic vessel density and lymph node metastasis in oral squamous cell carcinoma: Implications for use as a prognostic marker
- (2009) Sugiura INTERNATIONAL JOURNAL OF ONCOLOGY
- Randomized Phase II Trial of First-Line Treatment With Sorafenib Versus Interferon Alfa-2a in Patients With Metastatic Renal Cell Carcinoma
- (2009) Bernard Escudier et al. JOURNAL OF CLINICAL ONCOLOGY
- The role of VEGF-C/D and Flt-4 in the lymphatic metastasis of early-stage invasive cervical carcinoma
- (2009) Hao Yu et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Lymphangiogenesis and Its Relationship With Lymphatic Metastasis and Prognosis in Malignant Melanoma
- (2008) Baoquan Liu et al. Anatomical Record-Advances in Integrative Anatomy and Evolutionary Biology
- Suppression of Prostate Cancer Nodal and Systemic Metastasis by Blockade of the Lymphangiogenic Axis
- (2008) J. B. Burton et al. CANCER RESEARCH
- Vascular Endothelial Growth Factor C Stimulates Progression of Human Gastric Cancer via Both Autocrine and Paracrine Mechanisms
- (2008) M. Kodama et al. CLINICAL CANCER RESEARCH
- Blocking VEGFR-3 suppresses angiogenic sprouting and vascular network formation
- (2008) Tuomas Tammela et al. NATURE
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started